2008 was again a rewarding year for Boehringer Ingelheim. We again maintained our successful course as an independent and dynamically growing pharmaceutical company.

Our product pipeline has further improved and is being progressively filled with substances from our research. We focus on repiratory and cardiovascular diseases, central nervous system, immunology, metabolic diseases and oncology.

Read more and download our annual report here